We're making good strides in some areas and others are more resistant to breakthroughs. This even works in different aspects of the same thing: We have the abi

We're making good strides in some areas and others are more resistant to breakthroughs. This even works in different aspects of the same thing: We have the ability to genetically modify T-cells to kill some kinds of cancers, but it's more difficult to use that against solid tumors, which create their own microenvironments inside of them, than blood cancers. https://stemcellres.biomedcentral.com/articles/10.1186/s13287-020-02128-1#Sec16 https://stemcellres.biomedcentral.com/articles/10.1186/s1328... But, of course, we keep making progress, and there's been some promising results in making CAR T-cell therapies that work against solid tumors: https://www.cancernetwork.com/view/cldn6-car-t-cell-therapy-shows-positive-response-in-advanced-solid-tumors https://www.cancernetwork.com/view/cldn6-car-t-cell-therapy-... We advance piecemeal and some things are more difficult than others, but we definitely advance.